Heartflow (NASDAQ:HTFL – Get Free Report) had its price target upped by stock analysts at Canaccord Genuity Group from $56.00 to $69.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target would indicate a potential upside of 15.15% from the stock’s previous close.
HTFL has been the topic of several other research reports. Stifel Nicolaus increased their price target on Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Friday. Benchmark restated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Heartflow in a research report on Wednesday, November 4th. Morgan Stanley increased their target price on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Finally, Wells Fargo & Company increased their target price on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.25.
Check Out Our Latest Analysis on Heartflow
Heartflow Stock Up 1.4%
Shares of NASDAQ HTFL opened at $59.92 on Friday. The firm has a market cap of $5.21 billion, a PE ratio of -32.74 and a beta of 2.50. Heartflow has a 12-month low of $20.13 and a 12-month high of $60.65. The company’s fifty day simple moving average is $51.93 and its 200 day simple moving average is $35.14.
Heartflow (NASDAQ:HTFL – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business had revenue of $72.86 million during the quarter. During the same quarter in the previous year, the business posted ($0.27) earnings per share. On average, equities analysts predict that Heartflow will post -0.75 earnings per share for the current year.
Insider Buying and Selling at Heartflow
In other Heartflow news, CEO John Farquhar sold 38,900 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $49.57, for a total transaction of $1,928,273.00. Following the transaction, the chief executive officer directly owned 283,014 shares in the company, valued at approximately $14,029,003.98. This trade represents a 12.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 29,714 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $50.06, for a total value of $1,487,482.84. Following the transaction, the chief financial officer owned 184,789 shares in the company, valued at approximately $9,250,537.34. This trade represents a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 332,403 shares of company stock worth $16,602,786. Insiders own 7.70% of the company’s stock.
Institutional Trading of Heartflow
Several institutional investors and hedge funds have recently made changes to their positions in HTFL. GAMMA Investing LLC lifted its position in shares of Heartflow by 75.1% during the third quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after purchasing an additional 275 shares in the last quarter. Allworth Financial LP grew its position in Heartflow by 116.4% in the 3rd quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after purchasing an additional 616 shares in the last quarter. IFP Advisors Inc grew its position in Heartflow by 844.7% in the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock worth $40,000 after purchasing an additional 718 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Heartflow in the 2nd quarter valued at about $53,000. Finally, Mayport LLC increased its stake in Heartflow by 20.0% in the 2nd quarter. Mayport LLC now owns 12,000 shares of the company’s stock valued at $352,000 after buying an additional 2,000 shares during the last quarter.
Key Stories Impacting Heartflow
Investors following HTFL have been watching these stories:
- Positive Sentiment: Third-quarter revenue rose 57% year over year to $72.9 million, exceeding the roughly $65.2 million analyst estimate. The loss was $0.03 per share, narrower than both the expected $0.18 loss and the $0.27 loss a year earlier. HeartFlow Reports Q3 Loss, Beats Revenue Estimates
- Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.6 million consensus estimate. The higher outlook may signal stronger growth expectations. Heartflow Expects 2026 Revenue of $262M–$264M
- Negative Sentiment: CEO insider selling may weigh on sentiment: the CEO sold $2.17 million of Heartflow stock. A sale by itself does not establish the reason for the transaction. Heartflow CEO Sells $2.17 Million in Stock
About Heartflow
HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.
Featured Articles
- Five stocks we like better than Heartflow
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
